These findings indicate that DNAJC3-AS1 can regulate FASN via the EGFR/PI3K/AKT/NF-κB pathway to promote the progression of CRC and thus can be a candidate for molecular targeted therapy for CRC. The gene discussed is DNAJC3; the disease is colorectal carcinoma.